KNSA vs. AKRO, SUPN, INVA, ARQT, OCUL, OGN, BBIO, APLS, NUVL, and MDGL
Should you be buying Kiniksa Pharmaceuticals stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals include Akero Therapeutics (AKRO), Supernus Pharmaceuticals (SUPN), Innoviva (INVA), Arcutis Biotherapeutics (ARQT), Ocular Therapeutix (OCUL), Organon & Co. (OGN), BridgeBio Pharma (BBIO), Apellis Pharmaceuticals (APLS), Nuvalent (NUVL), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "pharmaceutical preparations" industry.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) and Akero Therapeutics (NASDAQ:AKRO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.
Kiniksa Pharmaceuticals has a net margin of 2.78% compared to Akero Therapeutics' net margin of 0.00%. Kiniksa Pharmaceuticals' return on equity of -7.26% beat Akero Therapeutics' return on equity.
Kiniksa Pharmaceuticals has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Kiniksa Pharmaceuticals presently has a consensus target price of $31.00, suggesting a potential upside of 62.64%. Akero Therapeutics has a consensus target price of $41.13, suggesting a potential upside of 78.65%. Given Akero Therapeutics' higher probable upside, analysts clearly believe Akero Therapeutics is more favorable than Kiniksa Pharmaceuticals.
54.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 54.6% of Kiniksa Pharmaceuticals shares are held by insiders. Comparatively, 7.9% of Akero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Kiniksa Pharmaceuticals received 67 more outperform votes than Akero Therapeutics when rated by MarketBeat users. Likewise, 64.34% of users gave Kiniksa Pharmaceuticals an outperform vote while only 61.49% of users gave Akero Therapeutics an outperform vote.
In the previous week, Akero Therapeutics had 31 more articles in the media than Kiniksa Pharmaceuticals. MarketBeat recorded 33 mentions for Akero Therapeutics and 2 mentions for Kiniksa Pharmaceuticals. Akero Therapeutics' average media sentiment score of 0.18 beat Kiniksa Pharmaceuticals' score of 0.00 indicating that Akero Therapeutics is being referred to more favorably in the news media.
Kiniksa Pharmaceuticals has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.31, suggesting that its stock price is 131% less volatile than the S&P 500.
Summary
Kiniksa Pharmaceuticals beats Akero Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Kiniksa Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KNSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kiniksa Pharmaceuticals Competitors List
Related Companies and Tools
